U.S. Markets closed

Healthcare Stocks are Gaining Ground in Technology Niche: Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Inovalon Holdings, NantKwest Inc.

CORAL GABLES, FL / ACCESSWIRE / November 8, 2018 / The US healthcare market is seeing a higher levels of acquisition activity as providers race to capitalize on innovation and deliver a better consumer experience. In fact, the global digital health market is expected to reach $665.36bn by 2026 growing at a CAGR of 15.4% during the forecast period, according toStratistics MRC*.

Many traditional providers are turning to IT partners with digital capabilities on automation and analytics to support and overcome the challenges they are facing. One of these challenges is the competition from new digital healthcare entrants.

To this end, Healthcare technology stocks are in focus this week and include Premier Health Group, Inc. (PHGRF) (PHGI), Inovalon Holdings (INOV) and NantKwest Inc. (NK)

Premier Health Group, Inc. (PHGRF) ( PHGI ) announced this week that as a part of its expansion plans it will enter the Pharmacy market via acquisition and/or launching a new Canada based pharmacy in H1-2019. With Premier's acquisition of HealthVue Medical Clinics in August, this could be the next phase of growth for the company. Furthermore, the Company expects to provide additional updates on acquisitions in Q4-18 and Q1-19. Premier Health Group, Inc. (PHGRF) (PHGI) is actively reviewing a pipeline of additional pharmacy partners, which include bricks and mortar locations for acquisition and strategic new retail opportunities for pharmacies.

"It is our position that the emergence of technology such as the ability for patients to electronically send their prescription(s) to a pharmacy for fulfillment and pick up at a later time or delivery directly to them at home or work will result in increased patient and consumer enrollment in apps that offer this type of functionality," said Dr. Essam Hamza, CEO of Premier.

Premier Health Group, Inc. (PHGRF) (PHGI) entered the primary care clinic and health care technology business via the HealthVue transaction. Premier obtained access to a group of four Greater Vancouver-based fully integrated, paperless and electronic-medical-record-based medical clinics with a 10-year history, 22 health care professionals and over 100,000 active patients.

For More Information On Premier Health Group, Click Here

Inovalon Holdings (INOV) reported third quarter results this week. Its Q3 revenue came in at $145.8 million and Non-GAAP net income of $16.3 million, resulting in Non-GAAP net income of $0.11 per share.

"We have seen an increasingly strong inflection in our business on many fronts over the recent months with significant increases in client retention rates, renewal performance, and new sales, all while concurrently continuing to expand value to clients and margin performance for the Company," said Keith Dunleavy, M.D., Inovalon's chief executive officer and chairman of the board.

"While the timing of some new and expanded business engagements has been later than we previously estimated, and the conversion of substantially all remaining legacy contracts to subscription-based contracts and discontinued pursuit of new legacy contracts impacted revenue for the few months remaining of the year, steep increases in multiple relevant metrics across the board are driving a strong 2019 outlook of 19% to 23% revenue growth, including organic growth of 12% to 14%, and strong Adjusted EBITDA, all with nearly 95% coverage visibility even at this early date."

Shares of Inovalon climbed to highs of $10.75 on Thursday.

For More Information On Inovalon, Click Here

NantKwest Inc. (NK) announced promising first human clinical results of 300 doses of CD16 targeted, off-the-shelf cryopreserved natural killer cells in a novel cancer memory vaccine immunotherapy this week.

Dr. Patrick Soon-Shiong, Chairman & CEO of NantKwest said, "High dose, uninformed, toxic chemotherapy damages the immune system and induces what is known as tolerogenic cell death. Natural Killer cells are the core innate immuno-protective mechanism against cancer. By developing a system of activating the patient's own Natural Killer cells and T cells, as well as augmenting the patient’s NK killing ability with engineering off-the- shelf NK transfusions, we hypothesize that resistant cancer can be overcome. We believe that current checkpoint inhibitors alone are insufficient to achieve long-term remission and only by inducing both the innate and adaptive immune system, and by orchestrating the treatment in a temporal-spatial sequence, will we induce T cell memory and long-term durable response. These early results of 300 doses of the Cancer Memory Vaccine in 30 patients over the course of the last 14 months are encouraging and suggest that we may be on the correct path to a paradigm change, leading ultimately to a chemo-free treatment of cancer patients, early in the course of their disease and ultimately to a path of cancer prevention."

Shares of NantKwest jumped to highs of $4.10 on Thursday; a move of more than 50%.

For More Information On NantKwest, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2018 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

*Stratistic MRC: https://www.reuters.com/brandfeatures/venture-capital/article?id=33613

Contact Information:


SOURCE: StockPrice.com